JFrog director Frederic Simon disposes of USD 11.64 million in common shares
Bitget2026/10/05 21:01JFrog director Frederic Simon sold 120,000 ordinary shares on Oct. 1, 2026 at prices of USD 96.37 to USD 99.75. Simon held 2,744,328 ordinary shares following the sales. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JFrog Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001823308-26-000015), on October 05, 2026, and is solely responsible for the information contained therein.
- JFrog director Frederic Simon sold 120,000 ordinary shares on Oct. 1, 2026 at prices of USD 96.37 to USD 99.75.
- Simon held 2,744,328 ordinary shares following the sales.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver price today: Silver broadly unchanged, according to FXStreet data
BUZZ - Berenberg downgrades Nike rating to "Sell", stock price falls
October 6th - ** Sportswear company Nike (NKE.N) saw its stock price drop about 1% in pre-market trading, quoted at $33.58 ** Berenberg Bank downgraded the stock from "buy" to "sell", cutting the target price from $49 to $27.50 ** Analyst Nick Anderson stated, "Nike seems to have accepted its declining position in sportswear," noting that the company plans to restructure its sportswear business around smaller business segments, which is interpreted as an acknowledgment that the market structure has "irreversibly" shifted against Nike ** The bank expects revenues to come under pressure until fiscal year 2028, management appears exhausted, and the “Pace” restructuring plan is unlikely to provide substantial help before fiscal year 2029; additionally, a recovery in the Chinese market is “far from guaranteed” ** Before this downgrade, S&P Global already lowered (link) its stock rating from "A+" to "A" this Monday and gave a "negative outlook," stating the company’s turnaround efforts (link) will require more time and higher investment ** Among 44 brokerages, 11 rate the stock as "buy" or higher, 25 as "hold," and 8 as "sell" or below; the median target price is $34.90—data compiled by London Stock Exchange Group (LSEG) ** As of the previous trading day's close, the stock had fallen about 47% year-to-date.
Are US Real Estate Stocks Dead? What the Charts and Rates Show
Hypertension drug developer Retension (RTSN.US) IPO priced at $11-13 per share, aiming to raise $40 million.
Retension Pharmaceuticals (RTSN.US) announced the terms of its initial public offering (IPO) on Monday.
Crypto prices
More
